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When characterizing a small renal mass (SRM), the main question to be answered is whether the mass represents a surgical or
nonsurgical lesion or, in some cases, if followup studies are a reasonable option. Is this a task for a urologist or a radiologist? It is
obvious that in the increasing clinical scenario where this decision has to be made, both specialists ought to work together. This
paper will focus on the principles, indications, and limitations of ultrasound, CT, and MRI to characterize an SRM in 2008 with a
detailed review of relevant literature. Special emphasis has been placed on aspects regarding the bidirectional information between
radiologists and urologists needed to achieve the best radiological approach to an SRM.
Copyright © 2008 A. Marhuenda et al. Thisis an open access article distributed under theCreative Commons AttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Overthelast3decades,therehasbeenarisingtrendtodeﬁne
small renal masses (SRMs) as masses below 4cm in diameter
[1], making it the major reason for the 126% increase in
incidence of renal cell carcinoma (RCC) in the United States.
The reason for that is well known; the increasing number of
imaging examinations performed for unrelated indications
with many renal neoplasms of small size and early stage
incidentally detected. Faced with this situation, urologists
do not only suggest surgery as 30 years ago, but also oﬀer
diﬀerent options to deal with the problem. Most of their
decisions are based on radiological characterization of the
SRM, as biopsies of these masses have not been completely
accepted by the international urological community.
So, evidently urologists have to ask their colleagues in
the Radiology Department to improve their explorations
expecting more and more extensive radiological reports
analyzingnotjustthepresenceofthemass.TheSMRanalysis
must be carried out by both a radiologist and an urologist, as
bidirectional information is extremely important to deﬁne
the most probable nature of the mass.
The accurate diagnosis of a renal mass depends on
many factors, including the clinical history; so there is some
clinical information that urologists have to report to their
radiologists:
(i) presence of a familial syndrome,
(ii) presence of a urological tract infectious disease
previousorconcomitanttothediagnosesoftheSRM,
(iii) presence of previous stone disease and related treat-
ments,
(iv) presence of previous renal trauma,
(v) presence of kidney disease and renal insuﬃciency.
A high-quality imaging examination, under the control
of a radiologist, is essential. The most accurate diagnosis
of a renal mass is then made according to the nature of
the imaging ﬁndings, the experience of the radiologist, and
the quality of the examination, as well as the exclusion of
conditions that can mimic a renal neoplasm. There are some
key points that, due to their therapeutic decision-making
importance, radiologists need to provide in their reports:
(i) signs suspecting fat involvement in an SRM,
(ii) metabolic behavior during the diﬀerent phases of CT
and MRI after contrast administration, allowing to
characterize benign SRM,
(iii) the need (or not) to complete studies with diﬀerent
techniques,2 Advances in Urology
(iv) accurate and standard (for followup in case of
watchful waiting policy) measurement of 3 diameters
of the SRM,
(v) signs of active tumoral tissue after conservative
treatments which do not remove the SRM,
(vi) diﬀerential diagnosis of residual tumour with com-
plications after partial nephrectomies and foreign
bodies used to achieve haemostasis.
Having established the collaboration between urologist
andradiologistforthisreviewpaper,theaimofthetwocom-
plementary chapters submitted for the SRM diagnoses and
characterization is to give some light on the new challenges
which face radiologists nowadays, extremely important for
the SRM management.
2. OBJECTIVES
Renal cell carcinoma and oncocytoma are indistinguishable
from each other at imaging. Many other renal lesions must
be considered, such as angiomyolipoma (AML), lymphoma,
metastatic disease, renal anomalies, and other pseudotumors
that can mimic renal cell carcinoma. Although it is possible
to make this diﬀerentiation by using the imaging ﬁndings
alone, the clinical history can often be very important in
making the correct diagnosis. In fact, before making a
diagnosis of renal cell carcinoma, one should be certain that
none of these possible mimickers of renal cell carcinoma are
potentially present.
Staging by TNM system can be considered a prognostic
classiﬁcation, and there is evidence that the smaller the size,
the better the prognosis [2, 3] . The increasing incidence of
renal mass manifestations of tumours that are conﬁned to
the renal capsule and relatively small in size has stimulated a
growing trend toward nephron-sparing surgical techniques,
as current data show survival rates comparable to those
associated with radical nephrectomy.
Imaging ﬁndings that can aﬀect the decision to perform
partial nephrectomy included tumor size in three planes:
tumor location within the kidney; presence of a pseudo-
capsule (a thin band of ﬁbrous tissue and compressed renal
parenchyma surrounding the lesion); tumor invasion of the
renal sinus fat, collecting system, renal vein, or perinephric
fat; presence of lymphadenopathy; morphologic and physio-
logic status of the contralateral kidney. All these aspects are
evaluated by means of diﬀerent imaging techniques.
The increased implementation of kidney-sparing surgery
for renal cell carcinoma may create an important role for
diagnostic imaging in the discovery of small synchronous
carcinomas. Radiologist should be aware of the possibility of
tumor multifocality or of adrenal metastases from a high-
grade small renal tumor as well as of the association of RCC
with lymphoma [4].
The challenge is to detect and delineate all lesions
to ensure complete surgical excision while preserving the
maximal amount of functioning parenchyma. For patients
who are not surgical candidates, imaging staging, along with
the other factors, can provide prognostic information.
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Figure 1:Simplecystasanechoiclesionwithasharplydeﬁnedback
wall and enhancement of through sound transmission.
3. ULTRASOUND
The fact that renal neoplasms have been detected earlier
and with increased frequency is well documented in the
literature [5, 6]. This is probably due to two major factors.
One factor is that there has been a considerable increase
in the number of people who undergo kidney imaging in
the general population because of the widespread use of
ultrasound (US). The other reason is that this imaging
technique is able to depict lesions of the kidneys that could
be missed with urography [7]. This increased detection of
renal neoplasms also results in the increased detection of
benign lesions and nonneoplastic masses, particularly renal
cysts. Therefore, the diﬀerentiation between a neoplastic and
a nonneoplastic lesion is a common dilemma.
To diﬀerentiate benign from malignant SRM can prove
even more problematic because the ﬁndings can also become
smaller, hence requiring more detailed and more sensitive
imaging studies.
Ultrasound plays an important role in the detection and
evaluation of these SRMs. While this technique may not be
as sensitive as contrast-enhanced CT or MR for revealing
SRM, US has been the initial technique in the discovery of
a large number of these incidentally discovered tumors when
the kidney is studied in the course of abdominal imaging.
Sonography is very accurate in distinguishing liquid from
solid tissue. Therefore, its major use in these small lesions
is to help diﬀerentiate small cysts (see Figure 1)f r o ms m a l l
solid tumors [8]. Maintaining rigid criteria is necessary to
maintain the high accuracy possible with this technique.
In the general population, renal cysts are the most
common space-occupying lesions in the kidney. With this
technique, 80% of detected renal masses are characterized as
simple cysts [9] thus ending their diagnostic evaluation. The
remaining 20% of renal masses require further study with
CT or MR imaging [10]. Any mass detected that does not
meet the strict sonographic criteria for a simple cyst should
be further evaluated with CT or MR imaging of the kidneys.A. Marhuenda et al. 3
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Figure 2: A cyst with nodular thickening of the wall and internal
septa.
However,oneortwothinseptationsmayalsobevisiblesono-
graphically in simple renal cysts [11]. Because these ﬁndings
are diagnostic, no further imaging or followup is needed
in the evaluation of these lesions. However, other atypical
features sonographically detected calciﬁcations; more than
two septations, septal thickening or nodularity, and the
presenceofsolidcomponentsindicatethatsonographyalone
will not be adequate for complete evaluation of these renal
masses (see Figure 2). The addition of Doppler sonography,
color Doppler sonography, power Doppler sonography [12,
13], and sonographic contrast agents may further improve
the detection and characterization of renal masses. However,
none of these techniques preclude the need for CT or MR
imaging of renal masses that do not meet the sonographic
criteria for diagnosis of a simple cyst.
In the study of solid renal masses, the role for US has
been mainly centred on the diﬀerentiation of RCC and
AML, which are the most common malignant and benign
solid renal tumors, respectively [14–17]. When a solid mass
is diagnosed, RCC or AML should be initially considered
because of the high frequency of their occurrence. At US,
most AML lesions are markedly hyperechoic relative to renal
parenchyma. They may appear less echogenic depending
on the relative proportion of fat, smooth muscle, vascular
components, and haemorrhage in the lesion [18, 19]. RCC
displays a broad range of echogenicities. Although often
thought of as hypoechoic or isoechoic, recent studies have
shown that most RCC are hyperechoic relative to renal
parenchyma and that up to 12% simulate AML [14–17].
Forman et al. [14] have shown that one third of small
RCC are as echogenic as a “classical” AML. An echotexture
equal to that of renal sinus fat seen in a small renal mass
is, therefore, no longer considered adequate to exclude the
diagnosis of malignancy (see Figure 3).
Other ultrasound signs have been used to diﬀerentiate
between hyperechoic RCC and AMLs. The presence of an
anechoicrimand/oranintratumoralcystisonlyseeninRCC
(see Figure 4). The presence of acoustic shadow is speciﬁc
of AML. However, the detectability of these ﬁndings varies
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Figure 3: Well-deﬁned hyperechoic small renal mass. Pathologic
analysis of the surgical specimen revealed a renal cell carcinoma.
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Figure 4: Well-deﬁned hyperechoic small renal mass with hypoe-
choic rim and intratumoral cystic area, conﬁrmed with pathologic
analysis as renal cell carcinoma.
[15, 16], their diagnostic value has not been established, and
the presence of these features is not suﬃcient to diﬀerentiate
RCC from the other solid renal masses that are incidentally
detected on gray-scale US. On the power Doppler US, the
analysis of the vascular distribution has not increased the
diagnostic accuracy for small renal tumors [12]. Contrast-
enhanced Doppler US can increase the detection of intra-
tumoral vascularity compared to color/power Doppler US
[20].However,theirsignalintensityhasnotbeenfoundtobe
suﬃciently intense for tumor characterization. Recently, the
development of contrast-enhanced harmonic US imaging
has provided a better assessment of the diagnostic accuracy
of RCC as compared with gray-scale US by allowing better
visualization of the intratumoral anechoic areas and the
pseudocapsule than can the gray-scale US [21], but there still
exists an overlapping of signs of RCC and the other solid
renal masses, making it necessary to use CT or MR imaging
in the study of small renal masses.4 Advances in Urology
4. CT
HelicalCTisgenerallyacceptedasthecriticalimagingtestfor
the classiﬁcation of renal masses. Radiation exposure is the
greatest disadvantage of this technique. MRI is comparable
to helical CT for detection, diagnosis, and staging of renal
masses. However, CT has the advantages of widespread
availability, shorter examination time, and lower cost in
comparison with MRI.
Ad e t a i l e da n a l y s i so fav a r i e t yo fC Tf e a t u r e si sr e q u i r e d ,
includingthesize,location,appearanceonunenhancedscan,
the presence and location of calciﬁcations, the presence and
size of a cyst wall or septations, and the amount and pattern
of contrast enhancement [7, 22, 23].
4.1. CTtechnique
Single detector and especially multidetector spiral (MDCT)
have reﬁned the diagnostic evaluation of renal patho-
logic conditions. Compared with single-detector helical CT,
MDCT allows the kidneys to be scanned with a collimation
of less than 5mm during a single breath hold [24]. From
a single data set obtained with thin collimation, both thin
and thick sections can be reconstructed and no additional
radiation exposure is required to obtain the thin sections.
This dataset is manipulated by using a workstation to pro-
duce volume-rendered and three-dimensional (3D) images
when necessary. The 3DCT images can be viewed in multiple
planes and orientations to deﬁne the lesion.
A triphasic imaging protocol consists of an unenhanced
phase through the kidneys, an arterial or corticomedullary
phase through the liver and kidneys (between 25 and 70
seconds after the start of injection of contrast), and a
portal venous or nephrographic phase of the entire abdomen
(between 80 and 180 seconds). Excretory phase (>180
seconds) is occasionally helpful.
An initial series of unenhanced scans provides a baseline
from which to measure the enhancement within the lesion.
The corticomedullary phase is useful to perform 3D
reconstructions and to depict the renal vasculature. Further-
more, this phase is considered essential for staging.
The nephrographic phase provides greater lesion detec-
tion and improved lesion characterization of renal masses
than corticomedullary phase [25, 26]. However, a case of
renalcellcarcinomavisibleonlyduringthecorticomedullary
phase has been shown in the literature [27]. The excretory
phase is occasionally helpful to better delineate the rela-
tionship of a centrally located mass within the collecting
system. Delayed scanning (15 minutes) can also be used in
lieu of unenhanced scanning to characterize an incidental
renallesiondetectedonaroutinecontrast-enhancedCTscan
[28].
At present, there is no worldwide agreement upon
the speciﬁc number that can be used as deﬁnitive and
unequivocal evidence of enhancement within a renal mass,
and it has been proposed by many authors that the
previously used threshold of 10HU should be increased to
20HU (a currently accepted criterion) (see Figure 5). Some
authors think that a renal mass that enhances 10–20HU is
indeterminate and needs further evaluation [29].
(a)
(b)
Figure 5: Hemorrhagic cyst. (a) Unenhanced CT scan shows a
hyperattenuating small renal mass (62H) (arrow). (b) Contrast-
enhanced CT scan during the nephrographic phase reveals light
enhancing (attenuation value increased 9H:71H) (arrow).
4.2. Imagingofspeciﬁcsmallrenalmasses
4.2.1. Cysts
Most small renal masses incidentally discovered on CT are
simple cortical cysts that need no further evaluation. The
Bosniak classiﬁcation system is used to asses the likelihood
of malignancy in cystic renal masses on the basis of lesion
complexity in CT imaging [30, 31]. Application of the
Bosniak classiﬁcation can be diﬃcult in the case of an
indeterminate renal lesion, especially if it is small. Bosniak
admits that distinction between category II (not requiring
surgery) and category III (requiring surgery) can be very
diﬃcult [32].
4.2.2. Angiomyolipoma
It is typically a solid lesion that exhibits fat density on CT
scans (−10 to –100HU) (see Figure 6). However, in some
cases, it may contain very small quantities of fat that can be
overlooked. Angiomyolipomas rarely contain calciﬁcation,
and, therefore, a diagnosis of angiomyolipoma should not
be made if a lesion contains fat and calcium [33, 34]. There
have been few case reports of fat from RCC that also contain
calciﬁcation. In such cases, a renal cell carcinoma must be
considered the most likely diagnosis.
4.2.3. Oncocytoma
It is usually a hypodense mass, homogeneous, with smooth
contours and a tendency to enhance avidly (see Figure 7).A. Marhuenda et al. 5
Figure 6: Angiomyolipoma. Contrast-enhanced CT shows a small
homogeneous fat-containing mass.
A
A:1 .63cm
Figure 7: Oncocytoma. Small mass isoattenuated to renal paren-
chyma after contrast.
Until now, an oncocytoma was suggested on postcontrast
CT by the presence of a central hypoenhancing scar.
Because of its lack of speciﬁcity, patient management has
been unaﬀected by the presence of this ﬁnding. Renal cell
carcinoma and oncocytoma are indistinguishable from each
other at imaging.
4.2.4. Renalcellcarcinoma
The imaging characteristics of RCC are extremely varied,
with masses ranging from cystic to solid, from homogeneous
to heterogeneous and necrotic, from small to large, and
from localized to extensive. The typical CT appearance of
small RCC is a homogeneously isodense/hypodense mass,
noncalciﬁed, with an attenuation value of 20HU or more,
that enhance avidly and early with contrast medium (see
Figure 8)[ 23]. The early-stage contrast enhancement is
believed to be caused by tumor angiogenesis. However, a
small proportion of RCC are hypovascular, and the amount
of enhancement may be minimal. Small RCC with a pre-
dominantly cystic growth pattern, necrosis, or calciﬁcations
(peripheral curvilinear or punctate central) are uncommon.
Areas of fat attenuation can be present within renal cell
carcinomas, but are uncommon in small tumors.
(a)
(b)
Figure 8: Small hyper vascular renal cell carcinoma. (a) Contrast-
enhanced CT shows small renal mass that enhances early in
corticomedullary phase. (b) Rapid washout in nephrographic
phase.
Furthermore, a small RCC can be hyperattenuating. If
the lesion is depicted only on enhanced CT, delayed scanning
can also be used. Macari and Bosniak [28]h a v es u g g e s t e d
that measurement of the washout of contrast material from
atleast15minutesallowsdiﬀerentiationbetweenhyperdense
cyst and renal neoplasms. The washout of 15HU or more
indicates that, excluding vascular abnormality, the mass is
solid. A lack of washout indicates that the mass is probably
a hyperattenuating cyst.
On the other hand, renal cortical tumors are family
neoplasms with distinct cytogenetic and molecular charac-
teristics and varying malignant potential. In the 1997 Hei-
delberg classiﬁcation, renal cell carcinoma was subdivided
in subtypes [35]. It has been suggested that certain imaging
features may be associated with diﬀerent subtypes of solid
renal cortical tumors [36, 37]. The most consistent ﬁnding
in these studies was that the degree of enhancement was the
mostvaluableparameterfordiﬀerentiationofRCCsubtypes,
as clear cell RCC enhance to a greater degree than other
subtypes, especially papillary RCC. Clear cell RCC is also
strongly associated with a mixed enhancement pattern of
both enhancing soft-tissue components and low-attenuation
areas (necrotic or cystic changes). When homogeneous or
peripheral enhancement is present, clear cell RCC is a less
likely diagnosis, and other cell types should be considered.6 Advances in Urology
Figure 9: Papillary renal cell carcinoma. Contrast-enhanced CT
shows smallhomogeneous massthatis mildandlessenhanced than
renal parenchyma does.
Notably, a majority of papillary tumours were either homo-
geneous or peripheral enhancement (see Figure 9). The
presence to neovascularity was mildly associated with more
aggressive tumor. The clear cell RCC (and oncocytomas)
enhanced avidly during the parenchymal phase; the chro-
mophobe RCC (and lipid poor angiomyolipoma) enhanced
moderately and papillary RCC enhance mildly.
4.2.5. Non-Hodgkin’slymphoma
Lymphoma can have a variable appearance and may on
occasion resemble renal cell carcinoma. Most frequently, it
manifestsasbilateralsolidrenalmasses,andinapatientwith
systemic lymphoma, the proper diagnosis is not diﬃcult.
Characteristically,lymphomaofteninﬁltratesintothekidney
via the renal sinus or surrounds the kidney. In a patient with
knownsystemiclymphomatowhomarenalmasswithimag-
ing is detected, systemic treatment for lymphoma should be
instituted. If the patient’s systemic disease responds, and the
renal mass does not respond, biopsy of the mass is indicated.
However, lymphoma may rarely manifest as a solitary renal
mass or a homogeneous inﬁltrating renal mass. In this case,
biopsy of the mass is indicated previous to systemic therapy.
4.2.6. Metastases
Metastatic disease to the kidney typically manifests as mul-
tiple bilateral renal masses, often associated with metastatic
disease to other organs. They are often poorly deﬁned
and inﬁltrate the renal parenchyma. With the appropriate
clinical history, the diagnosis is straightforward. However, in
a patient with a solitary renal mass (especially an inﬁltrating
mass) and history of previous malignancy, percutaneous
renal biopsy is indicated for a deﬁnitive diagnosis.
4.2.7. Benignmesenchymaltumors
Included leiomyomas, lipomas, ﬁbromas, and mixed mes-
enchymal nodules. They are usually small (< 1cm) lesions,
found in autopsies.
4.2.8. Pseudotumors
They include congenital anomalies (prominent renal col-
umns of Bertin, renal dimorphisms, and dromedary humps)
and acquired pseudotumors (hypertrophied normal renal
parenchyma).Thisconditionenhancesidenticallytothenor-
malrenalparenchyma.Inthesesituationsitprovesappropri-
ate to scan during the corticomedullary and nephrographic
phase.
4.2.9. Renalmassmimickers
These include inﬂammatory masses (including focal
pyelonephritis, renal abscess) and hematoma. A careful
evaluation with high-quality CT or MR examination
combined with the clinical context of the case and a
familiarity with this group of “lesions” should reveal its
true nature. Most hematomas are perinephric and are
surrounded by fat stranding. They may occasionally have a
masslike appearance, and some may not be discovered until
long time after the traumatism. Chronic hematomas can
have calciﬁcations and do not enhance.
4.3. Diagnosisandmanagementof
renalcallcarcinomawithMD-CT
CT remains the most widely available and single most
eﬀective modality for staging renal call carcinoma [38, 39].
3DCT combined with CT angiography has the potential
to provide all the critical information needed to plan
the surgical procedure. 3DCT images can be viewed in
multiples planes and orientations to deﬁne the tumor and
its relationship to the renal surface, the collecting system,
and adjacent organs. A 3DCT angiogram can be created to
delineate the renal arterial and venous anatomy.
Theanatomicextentofthetumoratthetimeofdiagnosis
is the single most important factor in determining prognosis
(see Table 1)[ 38].
Most urological surgeons continue to refer to Robson’s
classiﬁcation,whichisessentiallyasurgicalstagingapproach.
This system includes the important staging variables that
have survived scrutiny over the years. Conﬁnement within
the renal capsule, penetration into the perirenal fat, invasion
into the renal vein, and lymph node metastases are all
important in determining the prognosis.
Under and overstating of perinephric invasion are the
most common staging errors at CT [40]. The most speciﬁc
ﬁnding of stage T3a, the presence of an enhanced nodule in
theperinephricspace,ishighlyspeciﬁcbutalsolowsensitive.
The diﬀerentiation between stage T2 and T3a tumors is very
problematic.
If tumoral spread within the IVC is identiﬁed, precise
delineation of the superior extent of the thrombus is
essential for the surgeon to plan the optimal surgical strategy
for thrombectomy and minimize the risk of embolism.
The level of involvement of the IVC dictates the surgical
approach. Involvement of the IVC is best shown during
corticomedullary phase. Because of its multiplanar capabil-
ity, magnetic resonance imaging is the preferred modality
to image. However, the three-dimensional CT with sagittal
and coronal reconstructions is also eﬀective in depicting
the superior extent of inferior vena cava thrombus (see
Figure 10), with the advantages of widespread availability,A. Marhuenda et al. 7
Table 1: Staging system for renal carcinoma and CT criteria.
Tumour position Robson TNM CT ﬁndings
Conﬁned within I Soft-tissue mass enhances
renal capsule less than normal renal
Small (<7cm) T1 parenchyma; central
Large (≥7cm) T2 necrosis in large RCC.
II T3a
Perinephric stranding;
Spread to perinephric fat Perinephric collateral vessels;
Soft-tissue mass in perinephric space
Venous thrombus IIIA
Renal vein only T3b Low-attenuation ﬁlling defect vein;
IVC infradiaphragmatic T3c Direct continuity of thrombus with primary mass;
IVC supradiaphragmatic T4b Enhanced thrombus
Regional lymph IIIB N1-N3 Lymph nodes 1cm in diameter or larger
node metastases
Direct invasion of adjacent organs IV A T4a Obliteration of normal soft-tissues planes between tumor and adjacent organs
Distant metastases M1 Metastases enhance with IV contrast material;
Hepatic metastases best in arterial phase
IV: intravenous, IVC: inferior vena cava.
shorterexaminationtime,andlowercostincomparisonwith
MR [40].
5. MR
5.1. Indications
Although ultrasound and CT are often combined to reveal
and characterize most renal lesions, MR is sometimes
required when indeterminate lesions are found [41], or
when a hyperattenuating renal mass is observed on CT [42].
Furthermore, some renal masses are incidentally discovered
when MR imaging is performed to answer questions other
than urology ones.
On the other hand, MR imaging has been considered the
most accurate method for those patients with contraindica-
tions to iodinated contrast administration such as in patients
with renal failure and those with an allergy to iodinated
contrast material [43].
Recently, nephrogenic systemic ﬁbrosis was linked to
gadolinium contrast agent exposure in patients with renal
failure; therefore its use should be reserved for neurological
and vascular cases where the quality of information gained
was suﬃcient to justify the risk of potential devastating
adverse eﬀects [44]. Nevertheless, the better contrast reso-
lution of MR imaging, as opposed to CT, is an undoubtful
advantage in those patients for performing an MR explo-
ration, even though no contrast is provided.
MR imaging has been considered useful not only in
characterization but also in evaluation of most cystic renal
masses with the Bosniak classiﬁcation system [45]. In
addition, MR imaging can potentially improve staging and
preoperative studying of a renal mass [41, 46–51]a sw e l la s
tumor multifocality, collecting system invasion, and venous
invasion [52]. Moreover, MRI is capable of showing the
patency of a blood vessel without the use of intravenous
contrast medium.
The accuracy in detection and characterization of SRM
carries great signiﬁcance when nephron sparing surgery
is being considered for a renal cell carcinoma because
synchronouslesionsmeasuring1–15mmhavebeenreported
to a frequency as high as 19.7% [53].
5.2. Basictechnicalexamination
A proper technical examination is needed for studying a
renal mass which is indeterminate after US and CT tech-
niques. Owing to intrinsic proprieties of magnetic resonance
examination, high-quality renal MR imaging is dependent
on multiple factors, includingpatient cooperation in holding
breath. In patients referred for evaluation of a renal mass,
examinations are currently performed with a torso phased-
array coil, preferably during a more reproducibility end-
expiratory breath hold [29, 54].
Diﬀerent protocols can be used by diﬀerent institutions
depending on their technical requirements. Essentially, the
common aspects are shown as follows. Prior to con-
trast administration, sequences are used to obtain images
weighted on T1 and T2, in and out of phase T1, and
a precontrast 3D weighted T1 with fat saturation can be
acquired in diﬀerent planes, basically on axial plane but
also coronal or sagittal can be employed to best depict the
mass, especially for such lesions located in renal poles. This
approach is most important when evaluating a patient with
a solitary kidney that contains a renal neoplasm that is
amenable to partial nephrectomy.
These sequences provide us with morphologic informa-
tion about the renal parenchyma and a renal mass (location,
size, and signal intensity), parenchymal structures and
adjacentorgans,vascularstructuresandlymphadenopathies,8 Advances in Urology
(a)
(b)
Figure 10: Renal cell carcinoma. (a) Three-dimensional CT with
coronal reconstruction, (b) sagittal oblique reconstruction.
and are designed to improve visualization of tisular intrinsic
characteristics (ﬂuid, haemorrhage, fat, ﬁbrosis), except for
detecting calciﬁcation.
Use of gadolinium as a contrast agent has been described
as a higher detection and characterization of SRM with
MR imaging to a higher level than does contrast CT [55,
56]. After contrast administration, MR angiography, MR
venography, and MR urography are performed by using an
oblique coronal breath-hold 3D fat-suppressed dynamically
acquired T1-weighted spoiled sequence. The imaging delay
for MR angiography is based ona bolus test with a power
injector. MR venography and MR urography are performed
at approximately 30 seconds and 5 minutes after MR
angiography, respectively. The postcontrast acquisition is
performed between MR venography and MR urography.
For the characterization of renal masses and to determine
the presenceor absence of enhancement, most authors
recommend an imaging delay of 3–5 minutes [29].
These sequences are used to increase conspicuity of a
renal mass, and to depict the renal arteries and veins, for the
evaluation of the extent of the tumor in the perinephric fat
and the relationship of a renal tumor to the hilar vessels and
collecting system, which is helpful to the urologist in surgical
planning [49].
5.3. ImportantfeaturestorecognizeonMRimaging
5.3.1. Signalintensity
Most renal masses are hypointense on T1 and hyperintense
on T2-weighted images, reﬂecting their water content (ﬂuid,
oedema,etc.).Haemorrhageorinfectioncausesdiﬀerentand
heterogeneous signal intensities both on T1 and T2, depend-
ing on the age of the bleed or the protein concentration,
making diﬃcult the characterization of lesions.
In some cases, T1 hyperintensity and T2 hypointensity
renal lesions are noticed (see Figure 11), and most of
them are also hyperattenuating renal masses on unenhanced
CT. These are either benign or malignant masses and
include blood breakdown products or proteinaceous cysts,
haematomas and vascular malformations, and oncocytomas
or angiomyolipomas with minimal fat, but also some
malignant lesions such as RCC and lymphomas. Shinmoto
et al. [57] reported that papillary RCC is associated with T2-
hypointense appearance as well as hemosiderin deposition,
haemorrhage, and necrosis. When a solid hyperattenuated
renal mass is seen on unenhanced CT, an MR must be
performed to characterize the lesion looking for signal
loss on T2-weighted images owing to blood products, iron
deposits, hypercellularity, and proteinaceous content. MR is
helpful to recognize lesions that are otherwise impossible to
diﬀerentiate by CT alone, such as AML with minimal fat
and clear cell renal cell carcinomas. However, diﬀerentiation
between AML with minimal fat and papillary RCC is often
not always possible by MR, and a percutaneous biopsy may
be useful [42]. When a cystic mass is evaluated, MR may
show additional thickness of the septa and wall on T2-
weighted images than on CT [29].
5.3.2. Presenceoffattytissue
AMLs are the only solid renal tumors that can be positively
characterized using MR by demonstrating macroscopic fat
in the lesion, and this fact is basically useful in patients with
tuberoussclerosis,sincetheydevelopAMLandanincreasing
r i s ko fr e n a lc e l lc a r c i n o m a s[ 49] (see Figure 12).
Opposed phase images and spectral fat suppression are
useful in diﬀerentiating fat from haemorrhage containing
carcinomas causing high signal intensity on T1. Further-
more, in phase gradient echo images are often helpful
because the fatty portions of AML will be hyperintense and
renal clear cell carcinomas usually will not, although renal
cell carcinomas incidentally may be hyperintense on T1; in
these cases spectral fat suppression images should be used to
prove the presence of macroscopic fat in the AML [49].
Some renal lesions may contain very small amount of
fat, the so called “minimal fat AML,” with microscopic fat
and without demonstrable macroscopic fat (angiomyomas),
and it is not possible to diﬀerentiate from a renal neoplasm.
Fat suppression techniques generally are not helpful for
detecting fat in AML with minimal fat, because such massesA. Marhuenda et al. 9
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Figure 11: (a) Coronal haste T2 and (b) axial precontrast T1: small
lesion on medial aspect of the upper pole of the left kidney shows a
lowsignalintensityonT1andhyperintensityonT1,revealingblood
breakdown products consistent with haemorrhagic cyst.
contain little or no fat and often appear as isointense to the
renal parenchyma. Chemical shift imaging may be used to
determinate a small amount of fat within a mass, and can be
used to diﬀerentiate AML with minimal fat from other renal
neoplasms, with a high sensitivity and speciﬁcity [58].
However, a renal mass that is suppressed focally or
diﬀusely on opposed-phase sequences and that does not
exhibit fat suppression should arouse suspicion about the
possible presence of clear renal cell carcinoma due to
intracellularlipid[42].Obviously,thisdiﬀerentiationcannot
be made only with this unique technique and information of
other sequences, such as signal intensity on T2 and dynamic
gadolinium enhancement, and proper followup should
therefore take place. Kim et al. [58] suggested followup with
CT or MR imaging for two years after detection for such
lesions.
The presence of fat in clear cell carcinoma has been
used to diﬀerentiate subtypes of renal cell carcinoma because
this fact does not occur in oncocytoma and transitional cell
carcinoma [49], but if the tumor does not show signal loss, it
can still be a clear cell carcinoma.
5.3.3. Presenceofpseudocapsule
This is a pathologic feature composed of ﬁbrous tissue
and compressed renal parenchyma, seen frequently in the
early stages of a SRM. Although not speciﬁc (also seen
in some oncocytomas), it has been related to renal cell
carcinomas usually small and of low histologic grade, slow
growing, and less likely to metastasize [15]. Their presence
is an indicator of prognostic value [59]. This condition
allows renal parenchyma-sparing surgery, especially if sim-
ple enucleation is considered in patients with multiple
tumors, Von Hippel-Lindau disease or familial tendency for
RCC.
At MR, a pseudocapsule was seen as a hypointense thin
rim surrounding the tumor on both T1- and T2-weighted
images and is more diﬃcult to detect in hypointense tumors
[60, 61]. With postcontrast images, late enhancement of
the pseudocapsule resulted in poor contrast relative to the
surrounding tissue, lessening its own visualization in this
sequence (see Figure 13). Some reports [61, 62]n o t i c e d
that the presence of a pseudocapsule oﬀers an additional
value for local staging. On that series, T2-weighted imaging
was the most sensitive technique for visualization of the
pseudocapsule (sensitivity: 68%; speciﬁcity: 91%), and is
corroborated by other authors [15, 63, 64]. For this reasons,
MR shows a moderate to high sensitivity in depicting the
pseudocapsule thanCT [49].In some largetumors,although
tumorinvasionwasseen,aresidualpseudocapsulewasfound
in some areas.
5.3.4. Involvementofperinephricfat
This is a key point in treatment planning in modifying the
surgical approach from conservative to radical nephrectomy
(Robson’s stage I versus stage II). If partial nephrectomy
is considered, it is essential to know preoperatively if the
perinephricfatisinvadedornotbythetumor.AlthoughMRI
appears slightly more sensitive than CT, it is not speciﬁc in
distinguishing between these two stages.
The presence of an intact pseudocapsule is an indirect
sign of lack of perinephric fat invasion [61]. The overall
sensitivity of CT in detecting pseudocapsule is very low [62,
63, 65, 66], and MR had a pertinent accuracy for evaluating
possible involvement of perinephric fat using the aspect of
the pseudocapsule as an additional feature [61].
Perirenal fat invasion diagnosis was made when there
was loss of capsular integrity indicated by interruption of
the low signal intensity line around the kidney on T1-
and T2-weighted images and thick (>0.5mm) perinephric
stranding. Thin perinephric stranding and collateral vessel
formation alone were not considered features of perinephric
fat invasion. This causes under- and overstaging on CT and
MR and lacks good speciﬁcity [67]. It also may be caused
by edema, vascular engorgement, and/or inﬂammation [65].
The only highly speciﬁc ﬁnding was the presence of an
enhancing nodule or soft-tissue mass in the perinephric
space but this sign had only 46% sensitivity [38].
5.3.5. Enhancement
Diﬀerent patterns of enhancement have been observed, pre-
dominantly peripheral, heterogeneous, and homogeneous.
The dynamic evaluation appears to be useful in the detection10 Advances in Urology
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Figure 12: (a) Axial T1 in phase, (b) axial T1 out of phase, (c) axial haste T2 with fat saturation, and ((d–g) axial dynamic postcontrast
T1 (d), arterial; (e), venous; (f), nephrographic, and (g), excretory phase): right yuxtahilar renal lesion seen as a T1 hyperintense mass that
shows gross fat suppression on T2 revealing macroscopic fat and also probably small foci of peripheral fat as there is a small amount of signal
loss on out of phase sequence. On dynamic postcontrast images the mass shows a transitional highly peripheral enhancement in the non-fat
components with poor enhancement on the remaining postcontrast study. An angiomyolipoma was found at surgery.
and characterization of simple renal cysts and solid neo-
plasms [68].
The presence or absence of enhancement within a
renal mass is the most important factor in its proper
characterization. When a predominant part of a renal mass
enhances, the mass is considered solid and likely neoplastic.
Otherwise, it is important to be aware of the possibility of
pseudoenhancement and to know when to suspect it. All
solid lesions demonstrated gadolinium enhancement, not
only RCC and invasive transitional cell carcinomas but also
oncocytomas and AML (see Figures 12 and 14). Although
enhancement is suﬃcient for predicting malignancy, nonen-
hancement is not suﬃcient to exclude malignancy, and again
the integration of T2 appearance is useful in improving the
diﬀerentiation between benign from malignant renal lesions
[41].
Hypervascular RCC can be easily diﬀerentiated on
dynamic contrast-enhanced MR. Hypovascular RCC, AML,
and complicated cysts enhanced signiﬁcantly less than corti-
cal and medullary tissue did (see Figure 15). Furthermore,
papillary RCC is typically hypovascular and shows mild
contrast enhancement, whereas AML with minimal fat is
generally hypervascular and shows marked enhancement,
but occasionally the degree of enhancement varies, making
this diﬀerentiation diﬃcult [42]. Also hypovascular RCC
from the ﬁrst minute after gadolinium injection showed
signiﬁcantly greater enhancement than complicated cyst
[69].A. Marhuenda et al. 11
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Figure 13: (a) Axial stir and (b) axial postcontrast T1. A
pseudocapsule is seen as a hypointense rim surrounding the tumor
on T2 and is better delineated than on postcontrast T1 owing to the
late contrast enhancement of the pseudocapsule.
Thus, areas with haemorrhage or infection products do
not enhance but their signal intensity remains higher than
that of simple cyst, making quantitative ROI measurements
in these lesions essential [70] for correct characterization.
This can be made by quantitative and qualitative methods.
Ho et al. [71] concluded that above 15% was the optimal
percentage of enhancement threshold for distinguishing
cysts from malignancies. Although usually quantitative and
qualitativemethodsaresensitiveinthedetectionofenhance-
ment, in hyperintense lesions on unenhanced T1, qualitative
assessment based on image subtraction should be performed
to avoid false negative quantitative results [54].
When a cystic mass is evaluated, MR imaging may
demonstrate deﬁnitive enhancement that shows only equiv-
ocal enhancement on CT. In a cystic lesion with only a small
solid component, subtraction images may again be used to
betterassessthepresenceofenhancement[49].Furthermore,
even if detecting a calciﬁcation is a limitation on MR
imaging, it is however an advantage to determine whether
enhancementispresentinaheavilycalciﬁedcystonCTgiven
that it could be better appreciated [45]. The combination
of mural irregularity and intense mural enhancement is
a strong predictor of malignancy in renal cystic lesions
(see Figure 16). However, the appearance of benign and
malignant lesions may overlap [72, 73].
5.3.6. Other
Invasion of Gerota’s fascia was diagnosed when continuity of
the low signal intensity line around the perinephric fat on
T1-weighted images was disrupted by tumor. Imaging of the
ipsilateraladrenalglandandvenousspreadoftumorsareout
of the scope of this chapter, thus the clinical setting of small
renal tumors is not found incidentally, as it is the case in the
low probability of nodal metastases in this stage of disease.
On the other hand, advanced imaging techniques led
to improve the global accuracy for MDCT to adequately
stage these clinical aspects [38]. Hricak et al. [60]r e p o r t e d
accuracy rates for detecting adjacent organ invasion with
MRI, although, in their series, overstaging was caused by the
presenceofabnormalsignal,indistinctinterface,andabsence
of a free fat plane between the tumor and the adjacent organ.
5.4. Interpretationofimagesandsurgicalcriteria
When characterizing a renal mass, the major question to
be answeredis whether the mass represents a surgical or
nonsurgical lesion or, in some cases, if followup studies are
necessary.
Magnetic resonance imaging allows an accurate dif-
ferentiation between solid and cystic masses, as a ﬁrst
approximation, but angiomyolipomas are the only solid
renal tumors that can be positively characterized using MR.
Nevertheless, Prasad et al. [74] reported that small renal
medullary tumors may be diﬀerentiated from the more
common renal adenocarcinomas by their central location
and certain demographic characteristics. Furthermore, some
authors recently [75] analyzed the correlation between MR
imagefeaturesandhistopathologicalﬁndings,givingvalueto
subvoxel fat on chemical shift imaging as a good correlation
to clear cell type with a high speciﬁcity. These authors
reported that small size, peripheral location, low intratu-
moral signal intensity on T2, and low level enhancement
were also associated with low-grade papillary carcinomas.
Detection of macroscopic fat is the key for diagnosing
AML in the proper clinical setting, and it is decisive because
AML does not need to be surgically removed. The diagnosis
is made by demonstrating fat within a solid renal mass.
One pitfall of fat containing renal masses is the presence of
a renal cell carcinoma involving the perinephritic fat. This
diﬀerentiation is easily made if there is some calciﬁcation on
CT, as do some RCC [29]. However, calcium is not always
present in renal cell carcinoma [76].
The observation of a pseudocapsule surrounding a renal
cell carcinoma is a sign of lack of perinephric fat invasion,
and therefore it is more likely to predict that the tumor can
be removed by nephron sparing, so partial nephrectomy or
simple enucleation may be indicated when a pseudocapsule
is detected [49, 62].
T h ep r e s e n c eo fhaemorrhagic products may obscure
enhancement on dynamic postcontrast T1 images, and it
may also contribute to heterogeneity on T2 images. Thus,
in the setting of a T2 heterogeneous nonenhancing mass,
careful followup after an antibiotic trial may be a prudent
recommendation to avoid nephrectomy of renal abscess and12 Advances in Urology
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Figure 14: (a) Axial T1 in phase, (b) axial T1 out of phase, (c) axial stir, and (d–g) axial dynamic postcontrast T1 ((d) arterial; (e) venous; (f)
nephrographic, and (g) excretory phase). A nonfatty mass hyperintense on T2 and highly vascular on corticomedullary and nephrographic
phase with late mild washout as is shown on this clear renal cell carcinoma.
(a) (b) (c)
B
B:1 .47cm
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Figure 15: (a) Cor haste T2, (b) out of phase axial T1, (c) axial precontrast T1 with fat suppression, (d) early postcontrast axial T1 with
fat saturation, and (e) axial postcontrast T1 with fat suppression. Small renal lesion on the lateral aspect of the upper pole of the right
kidney shows a solid mass hypointense on T2 that does not present a loss of signal out of phase sequence and only a small enhancement on
postcontrast sequences, consistent with a papillary renal carcinoma.A. Marhuenda et al. 13
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Figure 16: (a) Coronal haste T2 and (b) late postcontrast coronal
T1 with fat saturation. Cystic lesion with an enhancing nodule on
the caudal aspect of the kidney. Renal cell carcinoma was found at
surgery.
to avoid misdiagnosis of a hemorrhagic renal cell carcinoma
[41]. Furthermore, a common occurrence of haemorrhage
is described in patients with renal cancer and/or in patients
with renal insuﬃciency, and caution should be exercised
whenevaluatinghaemorrhagiccysticlesionsinthesepatients
[77].
The most importantcriterion used in diﬀerentiating
surgical fromnonsurgical renalmasses is the determination
of enhancement [29]. Despite that, the lack of enhancement
of a renal lesion, particularly if small (<1cm), is not
considered a suﬃcient criterion for excluding malignancy,
as the haemorrhagic lesions occur, and in this setting,
T2-weighted images must be considered. Moreover, it is
important to combine the degree of enhancement with the
morphologicfeaturesofthelesion,suchashomogeneity,wall
thickening, and presence of calciﬁcations.
When a cystic mass is evaluated, a surgical cyst can
be suspected only if enhancement is present. Calciﬁcation
in a cystic renal mass is not as important in diagnosis as
the presence of associated enhancing soft-tissue elements
[78]. MR imaging may depict additional septa, thickening of
the wall and/or septa, or enhancement, which may lead to
an upgraded Bosniak cyst classiﬁcation and can aﬀect case
management [31, 49].
5.5. Limitations
As with all imaging techniques, it is extremely diﬃcult
with MR to determine whether malignant tissue extends
to adjacent normal tissue when strictly regular margins
are found because microscopic local invasion could have
occurred [61, 64]. Staging errors were made because of
limitations of the imaging technique: inability to detect
microscopic invasion of the perinephric fat, diﬃculty in
diﬀerentiating inﬂammatory changes from tumor inﬁltra-
tion,andinsensitivityindiﬀerentiatingsmallcollateralblood
vessels from tumor extension in the lymphatics [67].
There are also limitations to the detection of a pseudo-
capsule by MR, mainly with hypointense tumors because its
detection may be less accurate on T2-weighted owing to the
lack of delineation of the surrounding rim, as is the case of
some papillary tumors. With SRM, partial volume averaging
mayobscureitsvisualization,thusevaluationinthreeplanes,
and coronal, sagittal, or oblique views are required to avoid
this phenomenon on the upper and lower part of the tumor
[61]. Furthermore, given that the pseudocapsule was also
foundinoncocytomas,itisnotusefulfordiﬀerentiatingRCC
fromthisbenignsolidtumor,anditcannotbeusedtopredict
the nature of the lesion. But it can oﬀer an additional value
totheperformanceofpreoperativeMRtostagerenaltumors,
aiding to make decisions about the most appropriate surgical
technique to employ.
Concerning nodal staging, MR has the same limitations
as CT according to the nodal size over 1cm in short-axis
diameter, being this an additional indication for the future
use of new iron oxide-based contrast agents on MR to
improve speciﬁcity and accuracy in nodal staging [49, 79].
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